Imipenem FDA Link

Semisynthetic thienamycin that has a wide spectrum of antibacterial activity against gram-negative and gram-positive aerobic and anaerobic bacteria, including many multiresistant strains. It is stable to beta-lactamases. Clinical studies have demonstrated high efficacy in the treatment of infections of various body systems. Its effectiveness is enhanced when it is administered in combination with CILASTATIN, a renal dipeptidase inhibitor.

Also Known As:

Imipenem Anhydrous; Imipenem, Anhydrous; MK-0787; MK0787; Anhydrous Imipenem; Anhydrous, Imipenem; MK 0787; N Formimidoylthienamycin; Imipemide; N-Formimidoylthienamycin; 1- Azabicyclo(3.2.0)hept- 2- ene- 2- carboxylic acid, 6- (1- hydroxyethyl)- 3- ((2- ((iminomethyl)amino)ethyl)thio)- 7- oxo- , (5R-(5alpha,6alpha(R*)))-

Pharmalogical Action Categories:

Anti-Bacterial Agents

Organic Chemicals: 140
- Amides: 2487
  - Lactams: 2278
    - beta-Lactams: 2435
      - Carbapenems: 5149
        Thienamycins: 1
        Imipenem: 1713
Heterocyclic Compounds: 207
- Fused-Ring Heterocyclic Compounds
  - 2-Ring Heterocyclic Compounds
    - beta-Lactams: 2435
      - Carbapenems: 5149
        Thienamycins: 1
        Imipenem: 1713

Yosr Kadri Selected Research

Yosr Kadri Research Topics

Disease

Drug/Important Bio-Agent (IBA)

Therapy/Procedure